Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides

Table 5 Disease activity and ANCA titers at presentation, treatment and outcome in study groups.

	Patients with idiopathic vasculitides (n = 56)			Patients with antithyroid DIDs (n = 16)
	WG n = 29	MPA n = 23	CSSy n = 4	WG n = 1	MPA n = 3	LLD n = 12
BVAS	21.37	19.78	20.0	15	13. 0	-
cANCA, n	28	0	0	1	0	0
cANCA, l/titer, median	128	-	-	64	-	-
pANCA, n	1	23	4	-	3	12
pANCA,1/titer, median	64	256	128	-	128	256
Cyclophosphamide, n	29	23	4	1	2	0
Only corticosteroids n	0	0	0	0	1	2
cANCA after 6 months, 1/ titer, median	16*	-	-	8	-	-
pANCA after 6 months, 1/titer, median	8	16	-	-	32	128
CRF, n	14	10	1	0	1	0
TRF, n	2	6	0	0	1	0
Lethal outcome, n	11	2	0	0	0	0
Patients with relapses, n	23	22	2	0	0	0

*Median titer of 23 WG patients, six died at first presentation. BVAS, Birmingham Vasculitis Activity Score; cANCA, cytoplasmic antineutrophil cytoplasmic antibodies; CRF, chronic renal failure; CSS, Churg Strauss syndrome; DID, drug-induced autoimmune disease; LLD, lupus-like disease; MPA, microscopic polyangiitis; pANCA, perinuclear antineutrophil cytoplasmic antibodies; TRF, terminal renal failure; WG, Wegener's granulomatosis.

ISSN: 1478-6362